nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—polycystic ovary syndrome—Ethinyl Estradiol—prostate cancer	0.282	1	CpDpCtD
Drospirenone—AR—prostate cancer	0.11	0.722	CbGaD
Drospirenone—AR—Nilutamide—prostate cancer	0.0659	0.306	CbGbCtD
Drospirenone—AR—Bicalutamide—prostate cancer	0.0659	0.306	CbGbCtD
Drospirenone—AR—Flutamide—prostate cancer	0.0546	0.253	CbGbCtD
Drospirenone—Testosterone—Abiraterone—prostate cancer	0.0431	0.184	CrCrCtD
Drospirenone—PTGS2—prostate cancer	0.0423	0.278	CbGaD
Drospirenone—Formestane—Estrone—prostate cancer	0.0293	0.125	CrCrCtD
Drospirenone—Formestane—Conjugated Estrogens—prostate cancer	0.0258	0.11	CrCrCtD
Drospirenone—Testosterone Propionate—Estradiol valerate/Dienogest—prostate cancer	0.0242	0.104	CrCrCtD
Drospirenone—AR—Estradiol—prostate cancer	0.0227	0.105	CbGbCtD
Drospirenone—Testolactone—Estrone—prostate cancer	0.0183	0.0782	CrCrCtD
Drospirenone—Testosterone—Estramustine—prostate cancer	0.0179	0.0765	CrCrCtD
Drospirenone—Norethindrone—Ethinyl Estradiol—prostate cancer	0.0144	0.0615	CrCrCtD
Drospirenone—Testosterone—Estrone—prostate cancer	0.0142	0.0608	CrCrCtD
Drospirenone—Methyltestosterone—Ethinyl Estradiol—prostate cancer	0.0118	0.0505	CrCrCtD
Drospirenone—Testosterone—Estradiol—prostate cancer	0.0108	0.0461	CrCrCtD
Drospirenone—Potassium Canrenoate—Prednisone—prostate cancer	0.00688	0.0294	CrCrCtD
Drospirenone—PTGS2—Etoposide—prostate cancer	0.00664	0.0308	CbGbCtD
Drospirenone—Cortisone acetate—Prednisone—prostate cancer	0.0049	0.0209	CrCrCtD
Drospirenone—Testolactone—Prednisone—prostate cancer	0.00475	0.0203	CrCrCtD
Drospirenone—Methyltestosterone—Prednisone—prostate cancer	0.00415	0.0177	CrCrCtD
Drospirenone—Hydrocortisone—Prednisone—prostate cancer	0.00347	0.0148	CrCrCtD
Drospirenone—AR—penis—prostate cancer	0.00241	0.156	CbGeAlD
Drospirenone—AR—semen—prostate cancer	0.00229	0.148	CbGeAlD
Drospirenone—NR3C2—prostate gland—prostate cancer	0.000776	0.0503	CbGeAlD
Drospirenone—PGR—prostate gland—prostate cancer	0.000722	0.0467	CbGeAlD
Drospirenone—NR3C2—seminal vesicle—prostate cancer	0.000657	0.0425	CbGeAlD
Drospirenone—AR—prostate gland—prostate cancer	0.000575	0.0372	CbGeAlD
Drospirenone—PGR—epithelium—prostate cancer	0.00053	0.0343	CbGeAlD
Drospirenone—NR3C2—renal system—prostate cancer	0.000529	0.0343	CbGeAlD
Drospirenone—NR3C2—urethra—prostate cancer	0.00052	0.0336	CbGeAlD
Drospirenone—AR—seminal vesicle—prostate cancer	0.000486	0.0315	CbGeAlD
Drospirenone—BCHE—prostate gland—prostate cancer	0.000468	0.0303	CbGeAlD
Drospirenone—AR—epithelium—prostate cancer	0.000423	0.0273	CbGeAlD
Drospirenone—BCHE—seminal vesicle—prostate cancer	0.000396	0.0256	CbGeAlD
Drospirenone—AR—renal system—prostate cancer	0.000392	0.0254	CbGeAlD
Drospirenone—Cerebrovascular accident—Estrone—prostate cancer	0.000387	0.00633	CcSEcCtD
Drospirenone—AR—urethra—prostate cancer	0.000385	0.0249	CbGeAlD
Drospirenone—Embolism venous—Estradiol—prostate cancer	0.000383	0.00626	CcSEcCtD
Drospirenone—Mood swings—Estramustine—prostate cancer	0.000376	0.00615	CcSEcCtD
Drospirenone—Embolism—Conjugated Estrogens—prostate cancer	0.000376	0.00615	CcSEcCtD
Drospirenone—Migraine—Estrone—prostate cancer	0.000373	0.0061	CcSEcCtD
Drospirenone—PTGS2—prostate gland—prostate cancer	0.00036	0.0233	CbGeAlD
Drospirenone—Mood swings—Estrone—prostate cancer	0.000359	0.00587	CcSEcCtD
Drospirenone—NR3C2—testis—prostate cancer	0.000342	0.0221	CbGeAlD
Drospirenone—Thrombosis—Conjugated Estrogens—prostate cancer	0.000341	0.00558	CcSEcCtD
Drospirenone—Breast pain—Ethinyl Estradiol—prostate cancer	0.000339	0.00555	CcSEcCtD
Drospirenone—Cerebrovascular accident—Estradiol valerate/Dienogest—prostate cancer	0.000337	0.00552	CcSEcCtD
Drospirenone—Migraine—Estradiol valerate/Dienogest—prostate cancer	0.000326	0.00533	CcSEcCtD
Drospirenone—PGR—testis—prostate cancer	0.000318	0.0206	CbGeAlD
Drospirenone—Mood swings—Estradiol valerate/Dienogest—prostate cancer	0.000313	0.00513	CcSEcCtD
Drospirenone—PTGS2—seminal vesicle—prostate cancer	0.000305	0.0197	CbGeAlD
Drospirenone—Depression—Estramustine—prostate cancer	0.000305	0.00499	CcSEcCtD
Drospirenone—Acute coronary syndrome—Estramustine—prostate cancer	0.000301	0.00493	CcSEcCtD
Drospirenone—Embolism—Estradiol—prostate cancer	0.000301	0.00492	CcSEcCtD
Drospirenone—Myocardial infarction—Estramustine—prostate cancer	0.0003	0.0049	CcSEcCtD
Drospirenone—Breast disorder—Estradiol valerate/Dienogest—prostate cancer	0.000299	0.00489	CcSEcCtD
Drospirenone—Acute coronary syndrome—Abiraterone—prostate cancer	0.000293	0.00479	CcSEcCtD
Drospirenone—Depression—Estrone—prostate cancer	0.000291	0.00476	CcSEcCtD
Drospirenone—Myocardial infarction—Abiraterone—prostate cancer	0.000291	0.00476	CcSEcCtD
Drospirenone—Acute coronary syndrome—Estrone—prostate cancer	0.000288	0.00471	CcSEcCtD
Drospirenone—Myocardial infarction—Estrone—prostate cancer	0.000286	0.00468	CcSEcCtD
Drospirenone—Venous thromboembolism—Epirubicin—prostate cancer	0.000285	0.00467	CcSEcCtD
Drospirenone—Breast disorder—Degarelix—prostate cancer	0.000284	0.00465	CcSEcCtD
Drospirenone—Breast pain—Goserelin—prostate cancer	0.000279	0.00457	CcSEcCtD
Drospirenone—Breast pain—Conjugated Estrogens—prostate cancer	0.000276	0.00452	CcSEcCtD
Drospirenone—Thrombosis—Estradiol—prostate cancer	0.000273	0.00446	CcSEcCtD
Drospirenone—Depression—Nilutamide—prostate cancer	0.00027	0.00443	CcSEcCtD
Drospirenone—Breast disorder—Cabazitaxel—prostate cancer	0.000268	0.00438	CcSEcCtD
Drospirenone—PTGS2—epithelium—prostate cancer	0.000265	0.0171	CbGeAlD
Drospirenone—Venous thromboembolism—Doxorubicin—prostate cancer	0.000264	0.00432	CcSEcCtD
Drospirenone—Cerebrovascular accident—Bicalutamide—prostate cancer	0.000259	0.00424	CcSEcCtD
Drospirenone—Depression—Estradiol valerate/Dienogest—prostate cancer	0.000254	0.00416	CcSEcCtD
Drospirenone—AR—testis—prostate cancer	0.000253	0.0164	CbGeAlD
Drospirenone—Acute coronary syndrome—Estradiol valerate/Dienogest—prostate cancer	0.000251	0.00411	CcSEcCtD
Drospirenone—Myocardial infarction—Estradiol valerate/Dienogest—prostate cancer	0.00025	0.00409	CcSEcCtD
Drospirenone—NR3C2—lymph node—prostate cancer	0.000248	0.016	CbGeAlD
Drospirenone—Erythema multiforme—Estrone—prostate cancer	0.000248	0.00406	CcSEcCtD
Drospirenone—PTGS2—renal system—prostate cancer	0.000246	0.0159	CbGeAlD
Drospirenone—Angiopathy—Abiraterone—prostate cancer	0.000242	0.00396	CcSEcCtD
Drospirenone—Depression—Degarelix—prostate cancer	0.000242	0.00395	CcSEcCtD
Drospirenone—PTGS2—urethra—prostate cancer	0.000241	0.0156	CbGeAlD
Drospirenone—BCHE—bone marrow—prostate cancer	0.000241	0.0156	CbGeAlD
Drospirenone—Acute coronary syndrome—Degarelix—prostate cancer	0.000239	0.00391	CcSEcCtD
Drospirenone—Myocardial infarction—Degarelix—prostate cancer	0.000238	0.00389	CcSEcCtD
Drospirenone—Mental disorder—Abiraterone—prostate cancer	0.000234	0.00382	CcSEcCtD
Drospirenone—PGR—lymph node—prostate cancer	0.00023	0.0149	CbGeAlD
Drospirenone—Breast disorder—Bicalutamide—prostate cancer	0.00023	0.00376	CcSEcCtD
Drospirenone—Breast pain—Estradiol—prostate cancer	0.000221	0.00362	CcSEcCtD
Drospirenone—Cerebrovascular accident—Ethinyl Estradiol—prostate cancer	0.000219	0.00359	CcSEcCtD
Drospirenone—Erythema multiforme—Estradiol valerate/Dienogest—prostate cancer	0.000216	0.00354	CcSEcCtD
Drospirenone—Embolism venous—Prednisone—prostate cancer	0.000212	0.00348	CcSEcCtD
Drospirenone—Migraine—Ethinyl Estradiol—prostate cancer	0.000211	0.00346	CcSEcCtD
Drospirenone—Affect lability—Ethinyl Estradiol—prostate cancer	0.000211	0.00346	CcSEcCtD
Drospirenone—BCHE—testis—prostate cancer	0.000206	0.0133	CbGeAlD
Drospirenone—Mood swings—Ethinyl Estradiol—prostate cancer	0.000203	0.00333	CcSEcCtD
Drospirenone—Mental disorder—Estradiol valerate/Dienogest—prostate cancer	0.0002	0.00328	CcSEcCtD
Drospirenone—Angiopathy—Degarelix—prostate cancer	0.000197	0.00323	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Abiraterone—prostate cancer	0.000196	0.00321	CcSEcCtD
Drospirenone—Depression—Bicalutamide—prostate cancer	0.000195	0.0032	CcSEcCtD
Drospirenone—Breast disorder—Ethinyl Estradiol—prostate cancer	0.000194	0.00318	CcSEcCtD
Drospirenone—Embolism—Docetaxel—prostate cancer	0.000194	0.00317	CcSEcCtD
Drospirenone—Acute coronary syndrome—Bicalutamide—prostate cancer	0.000193	0.00316	CcSEcCtD
Drospirenone—Myocardial infarction—Bicalutamide—prostate cancer	0.000192	0.00314	CcSEcCtD
Drospirenone—Mental disorder—Degarelix—prostate cancer	0.000191	0.00312	CcSEcCtD
Drospirenone—Embolism—Capecitabine—prostate cancer	0.000188	0.00307	CcSEcCtD
Drospirenone—Angiopathy—Cabazitaxel—prostate cancer	0.000186	0.00304	CcSEcCtD
Drospirenone—PTGS2—bone marrow—prostate cancer	0.000186	0.012	CbGeAlD
Drospirenone—Skin disorder—Abiraterone—prostate cancer	0.000184	0.00301	CcSEcCtD
Drospirenone—AR—lymph node—prostate cancer	0.000184	0.0119	CbGeAlD
Drospirenone—Cerebrovascular accident—Goserelin—prostate cancer	0.00018	0.00295	CcSEcCtD
Drospirenone—Mental disorder—Cabazitaxel—prostate cancer	0.00018	0.00294	CcSEcCtD
Drospirenone—Cerebrovascular accident—Conjugated Estrogens—prostate cancer	0.000179	0.00292	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Flutamide—prostate cancer	0.000178	0.00292	CcSEcCtD
Drospirenone—Haemoglobin—Bicalutamide—prostate cancer	0.000177	0.00289	CcSEcCtD
Drospirenone—Haemorrhage—Bicalutamide—prostate cancer	0.000176	0.00288	CcSEcCtD
Drospirenone—Affect lability—Goserelin—prostate cancer	0.000174	0.00285	CcSEcCtD
Drospirenone—Migraine—Goserelin—prostate cancer	0.000174	0.00285	CcSEcCtD
Drospirenone—Migraine—Conjugated Estrogens—prostate cancer	0.000172	0.00282	CcSEcCtD
Drospirenone—Thrombosis—Capecitabine—prostate cancer	0.00017	0.00278	CcSEcCtD
Drospirenone—Mood swings—Goserelin—prostate cancer	0.000167	0.00274	CcSEcCtD
Drospirenone—Skin disorder—Flutamide—prostate cancer	0.000167	0.00274	CcSEcCtD
Drospirenone—Embolism—Prednisone—prostate cancer	0.000167	0.00273	CcSEcCtD
Drospirenone—Embolism venous—Epirubicin—prostate cancer	0.000166	0.00272	CcSEcCtD
Drospirenone—Mood swings—Conjugated Estrogens—prostate cancer	0.000166	0.00271	CcSEcCtD
Drospirenone—Depression—Ethinyl Estradiol—prostate cancer	0.000165	0.0027	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Abiraterone—prostate cancer	0.000163	0.00268	CcSEcCtD
Drospirenone—Acute coronary syndrome—Ethinyl Estradiol—prostate cancer	0.000163	0.00267	CcSEcCtD
Drospirenone—Myocardial infarction—Ethinyl Estradiol—prostate cancer	0.000162	0.00265	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—HSD3B2—prostate cancer	0.000162	0.0754	CrCbGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Degarelix—prostate cancer	0.00016	0.00262	CcSEcCtD
Drospirenone—Breast disorder—Goserelin—prostate cancer	0.00016	0.00261	CcSEcCtD
Drospirenone—Angiopathy—Bicalutamide—prostate cancer	0.000159	0.00261	CcSEcCtD
Drospirenone—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.000159	0.00261	CcSEcCtD
Drospirenone—Breast disorder—Conjugated Estrogens—prostate cancer	0.000158	0.00259	CcSEcCtD
Drospirenone—Mental disorder—Bicalutamide—prostate cancer	0.000154	0.00252	CcSEcCtD
Drospirenone—Embolism venous—Doxorubicin—prostate cancer	0.000154	0.00252	CcSEcCtD
Drospirenone—Nervous system disorder—Degarelix—prostate cancer	0.000152	0.00248	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Cabazitaxel—prostate cancer	0.000151	0.00247	CcSEcCtD
Drospirenone—Skin disorder—Degarelix—prostate cancer	0.00015	0.00246	CcSEcCtD
Drospirenone—BCHE—lymph node—prostate cancer	0.000149	0.00967	CbGeAlD
Drospirenone—Gastrointestinal disorder—Nilutamide—prostate cancer	0.000149	0.00244	CcSEcCtD
Drospirenone—Haemoglobin—Ethinyl Estradiol—prostate cancer	0.000149	0.00244	CcSEcCtD
Drospirenone—Haemorrhage—Ethinyl Estradiol—prostate cancer	0.000149	0.00243	CcSEcCtD
Drospirenone—Cerebrovascular accident—Estradiol—prostate cancer	0.000143	0.00234	CcSEcCtD
Drospirenone—Nervous system disorder—Cabazitaxel—prostate cancer	0.000143	0.00234	CcSEcCtD
Drospirenone—Skin disorder—Cabazitaxel—prostate cancer	0.000141	0.00231	CcSEcCtD
Drospirenone—Erythema multiforme—Ethinyl Estradiol—prostate cancer	0.00014	0.0023	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.00014	0.0023	CcSEcCtD
Drospirenone—Migraine—Estradiol—prostate cancer	0.000138	0.00226	CcSEcCtD
Drospirenone—Affect lability—Estradiol—prostate cancer	0.000138	0.00226	CcSEcCtD
Drospirenone—Depression—Goserelin—prostate cancer	0.000136	0.00222	CcSEcCtD
Drospirenone—Angiopathy—Ethinyl Estradiol—prostate cancer	0.000135	0.00221	CcSEcCtD
Drospirenone—Depression—Conjugated Estrogens—prostate cancer	0.000135	0.0022	CcSEcCtD
Drospirenone—Acute coronary syndrome—Goserelin—prostate cancer	0.000134	0.0022	CcSEcCtD
Drospirenone—Myocardial infarction—Goserelin—prostate cancer	0.000134	0.00218	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Degarelix—prostate cancer	0.000133	0.00218	CcSEcCtD
Drospirenone—Acute coronary syndrome—Conjugated Estrogens—prostate cancer	0.000133	0.00218	CcSEcCtD
Drospirenone—Mood swings—Estradiol—prostate cancer	0.000133	0.00217	CcSEcCtD
Drospirenone—Myocardial infarction—Conjugated Estrogens—prostate cancer	0.000132	0.00216	CcSEcCtD
Drospirenone—Embolism—Epirubicin—prostate cancer	0.000131	0.00214	CcSEcCtD
Drospirenone—Mental disorder—Ethinyl Estradiol—prostate cancer	0.00013	0.00213	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Bicalutamide—prostate cancer	0.000129	0.00212	CcSEcCtD
Drospirenone—Breast disorder—Estradiol—prostate cancer	0.000127	0.00207	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.000126	0.00206	CcSEcCtD
Drospirenone—Haemoglobin—Goserelin—prostate cancer	0.000123	0.00201	CcSEcCtD
Drospirenone—Nervous system disorder—Bicalutamide—prostate cancer	0.000122	0.002	CcSEcCtD
Drospirenone—Haemorrhage—Goserelin—prostate cancer	0.000122	0.002	CcSEcCtD
Drospirenone—Skin disorder—Bicalutamide—prostate cancer	0.000121	0.00199	CcSEcCtD
Drospirenone—Embolism—Doxorubicin—prostate cancer	0.000121	0.00198	CcSEcCtD
Drospirenone—Thrombosis—Epirubicin—prostate cancer	0.000118	0.00194	CcSEcCtD
Drospirenone—Nausea—Estramustine—prostate cancer	0.000116	0.0019	CcSEcCtD
Drospirenone—PTGS2—lymph node—prostate cancer	0.000115	0.00745	CbGeAlD
Drospirenone—Erythema multiforme—Conjugated Estrogens—prostate cancer	0.000115	0.00187	CcSEcCtD
Drospirenone—Angiopathy—Goserelin—prostate cancer	0.000111	0.00182	CcSEcCtD
Drospirenone—Nausea—Estrone—prostate cancer	0.000111	0.00181	CcSEcCtD
Drospirenone—Angiopathy—Conjugated Estrogens—prostate cancer	0.00011	0.0018	CcSEcCtD
Drospirenone—Thrombosis—Doxorubicin—prostate cancer	0.00011	0.00179	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—prostate cancer	0.000109	0.00179	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.000108	0.00176	CcSEcCtD
Drospirenone—Depression—Estradiol—prostate cancer	0.000108	0.00176	CcSEcCtD
Drospirenone—Mental disorder—Goserelin—prostate cancer	0.000107	0.00175	CcSEcCtD
Drospirenone—Acute coronary syndrome—Estradiol—prostate cancer	0.000106	0.00174	CcSEcCtD
Drospirenone—Mental disorder—Conjugated Estrogens—prostate cancer	0.000106	0.00174	CcSEcCtD
Drospirenone—Myocardial infarction—Estradiol—prostate cancer	0.000106	0.00173	CcSEcCtD
Drospirenone—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.000104	0.00169	CcSEcCtD
Drospirenone—Nausea—Nilutamide—prostate cancer	0.000103	0.00168	CcSEcCtD
Drospirenone—Skin disorder—Ethinyl Estradiol—prostate cancer	0.000103	0.00168	CcSEcCtD
Drospirenone—Nausea—Flutamide—prostate cancer	0.000102	0.00167	CcSEcCtD
Drospirenone—Acute coronary syndrome—Mitoxantrone—prostate cancer	9.92e-05	0.00162	CcSEcCtD
Drospirenone—Myocardial infarction—Mitoxantrone—prostate cancer	9.86e-05	0.00161	CcSEcCtD
Drospirenone—Haemoglobin—Estradiol—prostate cancer	9.74e-05	0.00159	CcSEcCtD
Drospirenone—Haemorrhage—Estradiol—prostate cancer	9.69e-05	0.00159	CcSEcCtD
Drospirenone—Nausea—Estradiol valerate/Dienogest—prostate cancer	9.66e-05	0.00158	CcSEcCtD
Drospirenone—Breast pain—Epirubicin—prostate cancer	9.61e-05	0.00157	CcSEcCtD
Drospirenone—Nausea—Degarelix—prostate cancer	9.18e-05	0.0015	CcSEcCtD
Drospirenone—Erythema multiforme—Estradiol—prostate cancer	9.17e-05	0.0015	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	9.11e-05	0.00149	CcSEcCtD
Drospirenone—Haemoglobin—Mitoxantrone—prostate cancer	9.08e-05	0.00149	CcSEcCtD
Drospirenone—Haemorrhage—Mitoxantrone—prostate cancer	9.03e-05	0.00148	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	9e-05	0.00147	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—AKR1C3—prostate cancer	8.98e-05	0.0418	CrCbGaD
Drospirenone—Cerebrovascular accident—Capecitabine—prostate cancer	8.92e-05	0.00146	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	8.91e-05	0.00146	CcSEcCtD
Drospirenone—Breast pain—Doxorubicin—prostate cancer	8.89e-05	0.00146	CcSEcCtD
Drospirenone—Migraine—Docetaxel—prostate cancer	8.88e-05	0.00145	CcSEcCtD
Drospirenone—Angiopathy—Estradiol—prostate cancer	8.8e-05	0.00144	CcSEcCtD
Drospirenone—Nausea—Cabazitaxel—prostate cancer	8.65e-05	0.00142	CcSEcCtD
Drospirenone—Migraine—Capecitabine—prostate cancer	8.6e-05	0.00141	CcSEcCtD
Drospirenone—Nervous system disorder—Goserelin—prostate cancer	8.52e-05	0.00139	CcSEcCtD
Drospirenone—Mental disorder—Estradiol—prostate cancer	8.49e-05	0.00139	CcSEcCtD
Drospirenone—Testosterone Propionate—CYP17A1—prostate cancer	8.46e-05	0.0394	CrCbGaD
Drospirenone—Nervous system disorder—Conjugated Estrogens—prostate cancer	8.44e-05	0.00138	CcSEcCtD
Drospirenone—Skin disorder—Goserelin—prostate cancer	8.44e-05	0.00138	CcSEcCtD
Drospirenone—Skin disorder—Conjugated Estrogens—prostate cancer	8.36e-05	0.00137	CcSEcCtD
Drospirenone—Hydrocortisone—ANXA1—prostate cancer	8.3e-05	0.0387	CrCbGaD
Drospirenone—Mood swings—Capecitabine—prostate cancer	8.28e-05	0.00135	CcSEcCtD
Drospirenone—Acute coronary syndrome—Etoposide—prostate cancer	8.25e-05	0.00135	CcSEcCtD
Drospirenone—Myocardial infarction—Etoposide—prostate cancer	8.2e-05	0.00134	CcSEcCtD
Drospirenone—Breast disorder—Docetaxel—prostate cancer	8.16e-05	0.00133	CcSEcCtD
Drospirenone—Testosterone—CYP3A43—prostate cancer	8.09e-05	0.0377	CrCbGaD
Drospirenone—Testolactone—CYP19A1—prostate cancer	7.92e-05	0.0369	CrCbGaD
Drospirenone—Breast disorder—Capecitabine—prostate cancer	7.9e-05	0.00129	CcSEcCtD
Drospirenone—Affect lability—Prednisone—prostate cancer	7.66e-05	0.00125	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	7.43e-05	0.00122	CcSEcCtD
Drospirenone—Nausea—Bicalutamide—prostate cancer	7.42e-05	0.00121	CcSEcCtD
Drospirenone—Mood swings—Prednisone—prostate cancer	7.37e-05	0.00121	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	7.13e-05	0.00117	CcSEcCtD
Drospirenone—Erythema multiforme—Etoposide—prostate cancer	7.1e-05	0.00116	CcSEcCtD
Drospirenone—Testosterone Propionate—COMT—prostate cancer	6.9e-05	0.0321	CrCbGaD
Drospirenone—Acute coronary syndrome—Docetaxel—prostate cancer	6.86e-05	0.00112	CcSEcCtD
Drospirenone—Myocardial infarction—Docetaxel—prostate cancer	6.82e-05	0.00112	CcSEcCtD
Drospirenone—Angiopathy—Etoposide—prostate cancer	6.82e-05	0.00112	CcSEcCtD
Drospirenone—Nervous system disorder—Estradiol—prostate cancer	6.75e-05	0.00111	CcSEcCtD
Drospirenone—Depression—Capecitabine—prostate cancer	6.71e-05	0.0011	CcSEcCtD
Drospirenone—Skin disorder—Estradiol—prostate cancer	6.69e-05	0.00109	CcSEcCtD
Drospirenone—Acute coronary syndrome—Capecitabine—prostate cancer	6.64e-05	0.00109	CcSEcCtD
Drospirenone—Myocardial infarction—Capecitabine—prostate cancer	6.6e-05	0.00108	CcSEcCtD
Drospirenone—Haemoglobin—Docetaxel—prostate cancer	6.28e-05	0.00103	CcSEcCtD
Drospirenone—Nausea—Ethinyl Estradiol—prostate cancer	6.27e-05	0.00103	CcSEcCtD
Drospirenone—Haemorrhage—Docetaxel—prostate cancer	6.24e-05	0.00102	CcSEcCtD
Drospirenone—Skin disorder—Mitoxantrone—prostate cancer	6.23e-05	0.00102	CcSEcCtD
Drospirenone—Cerebrovascular accident—Epirubicin—prostate cancer	6.21e-05	0.00102	CcSEcCtD
Drospirenone—Haemoglobin—Capecitabine—prostate cancer	6.08e-05	0.000994	CcSEcCtD
Drospirenone—Haemorrhage—Capecitabine—prostate cancer	6.05e-05	0.000989	CcSEcCtD
Drospirenone—Affect lability—Epirubicin—prostate cancer	5.99e-05	0.000981	CcSEcCtD
Drospirenone—Migraine—Epirubicin—prostate cancer	5.99e-05	0.000981	CcSEcCtD
Drospirenone—Depression—Prednisone—prostate cancer	5.98e-05	0.000979	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Estradiol—prostate cancer	5.95e-05	0.000973	CcSEcCtD
Drospirenone—Acute coronary syndrome—Prednisone—prostate cancer	5.91e-05	0.000968	CcSEcCtD
Drospirenone—Erythema multiforme—Docetaxel—prostate cancer	5.9e-05	0.000966	CcSEcCtD
Drospirenone—Myocardial infarction—Prednisone—prostate cancer	5.88e-05	0.000962	CcSEcCtD
Drospirenone—Eplerenone—CYP3A5—prostate cancer	5.81e-05	0.027	CrCbGaD
Drospirenone—Mood swings—Epirubicin—prostate cancer	5.77e-05	0.000944	CcSEcCtD
Drospirenone—Cerebrovascular accident—Doxorubicin—prostate cancer	5.75e-05	0.000941	CcSEcCtD
Drospirenone—Erythema multiforme—Capecitabine—prostate cancer	5.72e-05	0.000935	CcSEcCtD
Drospirenone—Angiopathy—Docetaxel—prostate cancer	5.66e-05	0.000927	CcSEcCtD
Drospirenone—Affect lability—Doxorubicin—prostate cancer	5.54e-05	0.000907	CcSEcCtD
Drospirenone—Migraine—Doxorubicin—prostate cancer	5.54e-05	0.000907	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	5.53e-05	0.000905	CcSEcCtD
Drospirenone—Breast disorder—Epirubicin—prostate cancer	5.5e-05	0.0009	CcSEcCtD
Drospirenone—Angiopathy—Capecitabine—prostate cancer	5.48e-05	0.000898	CcSEcCtD
Drospirenone—Mental disorder—Docetaxel—prostate cancer	5.47e-05	0.000895	CcSEcCtD
Drospirenone—Haemoglobin—Prednisone—prostate cancer	5.41e-05	0.000886	CcSEcCtD
Drospirenone—Haemorrhage—Prednisone—prostate cancer	5.38e-05	0.000881	CcSEcCtD
Drospirenone—Medrysone—NR3C1—prostate cancer	5.38e-05	0.025	CrCbGaD
Drospirenone—Mood swings—Doxorubicin—prostate cancer	5.34e-05	0.000873	CcSEcCtD
Drospirenone—Mental disorder—Capecitabine—prostate cancer	5.3e-05	0.000867	CcSEcCtD
Drospirenone—Flurandrenolide—NR3C1—prostate cancer	5.19e-05	0.0242	CrCbGaD
Drospirenone—Skin disorder—Etoposide—prostate cancer	5.18e-05	0.000848	CcSEcCtD
Drospirenone—Nausea—Goserelin—prostate cancer	5.16e-05	0.000844	CcSEcCtD
Drospirenone—Testosterone Propionate—AR—prostate cancer	5.14e-05	0.024	CrCbGaD
Drospirenone—Nausea—Conjugated Estrogens—prostate cancer	5.11e-05	0.000836	CcSEcCtD
Drospirenone—Breast disorder—Doxorubicin—prostate cancer	5.09e-05	0.000833	CcSEcCtD
Drospirenone—Spironolactone—SHBG—prostate cancer	4.98e-05	0.0232	CrCbGaD
Drospirenone—Cortisone acetate—NR3C1—prostate cancer	4.94e-05	0.023	CrCbGaD
Drospirenone—Angiopathy—Prednisone—prostate cancer	4.89e-05	0.000799	CcSEcCtD
Drospirenone—Megestrol acetate—NR3C1—prostate cancer	4.76e-05	0.0222	CrCbGaD
Drospirenone—Mental disorder—Prednisone—prostate cancer	4.72e-05	0.000772	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—SHBG—prostate cancer	4.66e-05	0.0217	CrCbGaD
Drospirenone—Norethindrone—SHBG—prostate cancer	4.62e-05	0.0215	CrCbGaD
Drospirenone—Gastrointestinal disorder—Etoposide—prostate cancer	4.61e-05	0.000754	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	4.6e-05	0.000752	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	4.45e-05	0.000728	CcSEcCtD
Drospirenone—Methyltestosterone—SHBG—prostate cancer	4.39e-05	0.0204	CrCbGaD
Drospirenone—Spironolactone—AR—prostate cancer	4.36e-05	0.0203	CrCbGaD
Drospirenone—Nervous system disorder—Docetaxel—prostate cancer	4.35e-05	0.000712	CcSEcCtD
Drospirenone—Skin disorder—Docetaxel—prostate cancer	4.31e-05	0.000705	CcSEcCtD
Drospirenone—Haemoglobin—Epirubicin—prostate cancer	4.23e-05	0.000693	CcSEcCtD
Drospirenone—Nervous system disorder—Capecitabine—prostate cancer	4.21e-05	0.000689	CcSEcCtD
Drospirenone—Haemorrhage—Epirubicin—prostate cancer	4.21e-05	0.000689	CcSEcCtD
Drospirenone—Skin disorder—Capecitabine—prostate cancer	4.17e-05	0.000683	CcSEcCtD
Drospirenone—Nausea—Estradiol—prostate cancer	4.09e-05	0.000669	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—AR—prostate cancer	4.09e-05	0.019	CrCbGaD
Drospirenone—Erythema multiforme—Epirubicin—prostate cancer	3.98e-05	0.000652	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.96e-05	0.000649	CcSEcCtD
Drospirenone—Haemoglobin—Doxorubicin—prostate cancer	3.92e-05	0.000641	CcSEcCtD
Drospirenone—Haemorrhage—Doxorubicin—prostate cancer	3.9e-05	0.000638	CcSEcCtD
Drospirenone—Progesterone—CYP17A1—prostate cancer	3.89e-05	0.0181	CrCbGaD
Drospirenone—Methyltestosterone—AR—prostate cancer	3.85e-05	0.0179	CrCbGaD
Drospirenone—Gastrointestinal disorder—Docetaxel—prostate cancer	3.83e-05	0.000627	CcSEcCtD
Drospirenone—Angiopathy—Epirubicin—prostate cancer	3.82e-05	0.000625	CcSEcCtD
Drospirenone—Nausea—Mitoxantrone—prostate cancer	3.81e-05	0.000624	CcSEcCtD
Drospirenone—Nervous system disorder—Prednisone—prostate cancer	3.75e-05	0.000614	CcSEcCtD
Drospirenone—Skin disorder—Prednisone—prostate cancer	3.72e-05	0.000608	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Capecitabine—prostate cancer	3.71e-05	0.000607	CcSEcCtD
Drospirenone—Progesterone—SLC22A3—prostate cancer	3.71e-05	0.0173	CrCbGaD
Drospirenone—Mental disorder—Epirubicin—prostate cancer	3.69e-05	0.000604	CcSEcCtD
Drospirenone—Erythema multiforme—Doxorubicin—prostate cancer	3.68e-05	0.000603	CcSEcCtD
Drospirenone—Norethindrone—CYP3A5—prostate cancer	3.68e-05	0.0171	CrCbGaD
Drospirenone—Angiopathy—Doxorubicin—prostate cancer	3.54e-05	0.000579	CcSEcCtD
Drospirenone—Testosterone—SLC22A3—prostate cancer	3.5e-05	0.0163	CrCbGaD
Drospirenone—Mental disorder—Doxorubicin—prostate cancer	3.41e-05	0.000559	CcSEcCtD
Drospirenone—Hydrocortisone—SHBG—prostate cancer	3.31e-05	0.0154	CrCbGaD
Drospirenone—Methyltestosterone—CYP19A1—prostate cancer	3.22e-05	0.015	CrCbGaD
Drospirenone—Nausea—Etoposide—prostate cancer	3.17e-05	0.000519	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—ESR1—prostate cancer	3.15e-05	0.0147	CrCbGaD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.1e-05	0.000507	CcSEcCtD
Drospirenone—Spironolactone—NR3C1—prostate cancer	2.96e-05	0.0138	CrCbGaD
Drospirenone—Nervous system disorder—Epirubicin—prostate cancer	2.93e-05	0.00048	CcSEcCtD
Drospirenone—Skin disorder—Epirubicin—prostate cancer	2.91e-05	0.000476	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.87e-05	0.000469	CcSEcCtD
Drospirenone—Cortisone acetate—CYP3A4—prostate cancer	2.86e-05	0.0133	CrCbGaD
Drospirenone—Medroxyprogesterone Acetate—NR3C1—prostate cancer	2.77e-05	0.0129	CrCbGaD
Drospirenone—Nervous system disorder—Doxorubicin—prostate cancer	2.72e-05	0.000444	CcSEcCtD
Drospirenone—Progesterone—SHBG—prostate cancer	2.69e-05	0.0125	CrCbGaD
Drospirenone—Progesterone—CYP1B1—prostate cancer	2.69e-05	0.0125	CrCbGaD
Drospirenone—Skin disorder—Doxorubicin—prostate cancer	2.69e-05	0.00044	CcSEcCtD
Drospirenone—Progesterone—SLC22A1—prostate cancer	2.66e-05	0.0124	CrCbGaD
Drospirenone—Nausea—Docetaxel—prostate cancer	2.63e-05	0.000431	CcSEcCtD
Drospirenone—Hydrocortisone—CYP3A5—prostate cancer	2.63e-05	0.0123	CrCbGaD
Drospirenone—Gastrointestinal disorder—Epirubicin—prostate cancer	2.58e-05	0.000423	CcSEcCtD
Drospirenone—Nausea—Capecitabine—prostate cancer	2.55e-05	0.000417	CcSEcCtD
Drospirenone—Testosterone—SHBG—prostate cancer	2.55e-05	0.0119	CrCbGaD
Drospirenone—Testosterone—CYP1B1—prostate cancer	2.55e-05	0.0119	CrCbGaD
Drospirenone—Eplerenone—CYP3A4—prostate cancer	2.51e-05	0.0117	CrCbGaD
Drospirenone—Testosterone—SLC22A1—prostate cancer	2.51e-05	0.0117	CrCbGaD
Drospirenone—Norethindrone—CYP2C19—prostate cancer	2.51e-05	0.0117	CrCbGaD
Drospirenone—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.39e-05	0.000391	CcSEcCtD
Drospirenone—Progesterone—AR—prostate cancer	2.36e-05	0.011	CrCbGaD
Drospirenone—Nausea—Prednisone—prostate cancer	2.27e-05	0.000372	CcSEcCtD
Drospirenone—Testosterone—AR—prostate cancer	2.23e-05	0.0104	CrCbGaD
Drospirenone—Progesterone—CYP3A5—prostate cancer	2.14e-05	0.00999	CrCbGaD
Drospirenone—Progesterone—CYP2A6—prostate cancer	2.08e-05	0.00967	CrCbGaD
Drospirenone—Testosterone—CYP3A5—prostate cancer	2.03e-05	0.00944	CrCbGaD
Drospirenone—Hydrocortisone—NR3C1—prostate cancer	1.97e-05	0.00915	CrCbGaD
Drospirenone—Testosterone—CYP19A1—prostate cancer	1.87e-05	0.0087	CrCbGaD
Drospirenone—Progesterone—ESR1—prostate cancer	1.82e-05	0.00847	CrCbGaD
Drospirenone—Nausea—Epirubicin—prostate cancer	1.78e-05	0.000291	CcSEcCtD
Drospirenone—Nausea—Doxorubicin—prostate cancer	1.64e-05	0.000269	CcSEcCtD
Drospirenone—Medroxyprogesterone Acetate—CYP3A4—prostate cancer	1.61e-05	0.00749	CrCbGaD
Drospirenone—Progesterone—NR3C1—prostate cancer	1.6e-05	0.00746	CrCbGaD
Drospirenone—Norethindrone—CYP3A4—prostate cancer	1.59e-05	0.00742	CrCbGaD
Drospirenone—Methyltestosterone—CYP3A4—prostate cancer	1.51e-05	0.00705	CrCbGaD
Drospirenone—Progesterone—CYP2C19—prostate cancer	1.46e-05	0.0068	CrCbGaD
Drospirenone—Progesterone—CYP1A1—prostate cancer	1.45e-05	0.00677	CrCbGaD
Drospirenone—Testosterone—CYP2C19—prostate cancer	1.38e-05	0.00643	CrCbGaD
Drospirenone—Testosterone—CYP1A1—prostate cancer	1.37e-05	0.0064	CrCbGaD
Drospirenone—Hydrocortisone—CYP3A4—prostate cancer	1.14e-05	0.00531	CrCbGaD
Drospirenone—Progesterone—CYP3A4—prostate cancer	9.28e-06	0.00432	CrCbGaD
Drospirenone—Testosterone—CYP3A4—prostate cancer	8.78e-06	0.00409	CrCbGaD
Drospirenone—BCHE—Metabolism—AKR1C3—prostate cancer	4.6e-06	0.000122	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	4.6e-06	0.000122	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FGF10—prostate cancer	4.58e-06	0.000122	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PRKACB—prostate cancer	4.58e-06	0.000121	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—TBXAS1—prostate cancer	4.57e-06	0.000121	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTA4—prostate cancer	4.57e-06	0.000121	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ADRB2—prostate cancer	4.54e-06	0.00012	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP17A1—prostate cancer	4.53e-06	0.00012	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HIST1H4H—prostate cancer	4.52e-06	0.00012	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NPPA—prostate cancer	4.52e-06	0.00012	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	4.51e-06	0.00012	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.47e-06	0.000119	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	4.47e-06	0.000118	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTA2—prostate cancer	4.45e-06	0.000118	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—VAV3—prostate cancer	4.42e-06	0.000117	CbGpPWpGaD
Drospirenone—AR—Gene Expression—ERCC2—prostate cancer	4.41e-06	0.000117	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—SULT1A1—prostate cancer	4.4e-06	0.000117	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ABCG5—prostate cancer	4.4e-06	0.000117	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TGFBR2—prostate cancer	4.36e-06	0.000116	CbGpPWpGaD
Drospirenone—AR—Gene Expression—NR3C1—prostate cancer	4.34e-06	0.000115	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NCOA2—prostate cancer	4.32e-06	0.000114	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTA1—prostate cancer	4.3e-06	0.000114	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ITPR1—prostate cancer	4.29e-06	0.000114	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	4.26e-06	0.000113	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—HSD3B2—prostate cancer	4.25e-06	0.000113	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NAT2—prostate cancer	4.25e-06	0.000113	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTO1—prostate cancer	4.25e-06	0.000113	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—CREBBP—prostate cancer	4.24e-06	0.000112	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—INS—prostate cancer	4.16e-06	0.00011	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—MYC—prostate cancer	4.13e-06	0.00011	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—SLC5A5—prostate cancer	4.12e-06	0.000109	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IGF1R—prostate cancer	4.1e-06	0.000109	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	4.09e-06	0.000108	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PLCB2—prostate cancer	4.07e-06	0.000108	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP2C18—prostate cancer	4.07e-06	0.000108	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—LRP2—prostate cancer	4.07e-06	0.000108	CbGpPWpGaD
Drospirenone—AR—Gene Expression—PPARA—prostate cancer	4.07e-06	0.000108	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP2E1—prostate cancer	4.02e-06	0.000107	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—IGF1—prostate cancer	4.02e-06	0.000107	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—P4HB—prostate cancer	4e-06	0.000106	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—MYC—prostate cancer	3.98e-06	0.000106	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NQO1—prostate cancer	3.98e-06	0.000105	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—SERPINE1—prostate cancer	3.98e-06	0.000105	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—LPL—prostate cancer	3.93e-06	0.000104	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—TH—prostate cancer	3.92e-06	0.000104	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	3.91e-06	0.000104	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PDGFRB—prostate cancer	3.9e-06	0.000103	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.9e-06	0.000103	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—MMP2—prostate cancer	3.89e-06	0.000103	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—SLC22A1—prostate cancer	3.89e-06	0.000103	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP3A4—prostate cancer	3.88e-06	0.000103	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.86e-06	0.000102	CbGpPWpGaD
Drospirenone—PTGS2—Disease—B2M—prostate cancer	3.85e-06	0.000102	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TGFBR1—prostate cancer	3.85e-06	0.000102	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	3.84e-06	0.000102	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP1B1—prostate cancer	3.81e-06	0.000101	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ITGB3—prostate cancer	3.8e-06	0.000101	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—SULT2A1—prostate cancer	3.79e-06	0.0001	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	3.79e-06	0.0001	CbGpPWpGaD
Drospirenone—PTGS2—Disease—AKR1C3—prostate cancer	3.78e-06	0.0001	CbGpPWpGaD
Drospirenone—PTGS2—Disease—RPS19—prostate cancer	3.78e-06	0.0001	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PRKACB—prostate cancer	3.76e-06	9.98e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—MED12—prostate cancer	3.73e-06	9.88e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GNG5—prostate cancer	3.7e-06	9.8e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GGT1—prostate cancer	3.69e-06	9.79e-05	CbGpPWpGaD
Drospirenone—AR—Gene Expression—ESR1—prostate cancer	3.69e-06	9.78e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ERBB3—prostate cancer	3.68e-06	9.77e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FGFR2—prostate cancer	3.68e-06	9.75e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PPP3CA—prostate cancer	3.67e-06	9.73e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NCOA1—prostate cancer	3.64e-06	9.65e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP19A1—prostate cancer	3.59e-06	9.51e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NCOA3—prostate cancer	3.56e-06	9.44e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PRKCZ—prostate cancer	3.55e-06	9.41e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TERT—prostate cancer	3.53e-06	9.36e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	3.5e-06	9.28e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CALR—prostate cancer	3.49e-06	9.24e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—RXRA—prostate cancer	3.46e-06	9.18e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PARP1—prostate cancer	3.43e-06	9.09e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FGFR4—prostate cancer	3.43e-06	9.09e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—HPGDS—prostate cancer	3.4e-06	9.01e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CALCA—prostate cancer	3.39e-06	8.98e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—HIF1A—prostate cancer	3.38e-06	8.95e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP2C19—prostate cancer	3.38e-06	8.95e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.37e-06	8.93e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—COMT—prostate cancer	3.33e-06	8.84e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTP1—prostate cancer	3.32e-06	8.8e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—LEP—prostate cancer	3.3e-06	8.74e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTT1—prostate cancer	3.29e-06	8.74e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ACHE—prostate cancer	3.29e-06	8.74e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CAV1—prostate cancer	3.27e-06	8.66e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ITPR1—prostate cancer	3.27e-06	8.66e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP2A6—prostate cancer	3.26e-06	8.64e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HSPA1A—prostate cancer	3.25e-06	8.61e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.24e-06	8.6e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—CXCL8—prostate cancer	3.23e-06	8.58e-05	CbGpPWpGaD
Drospirenone—AR—Gene Expression—CREBBP—prostate cancer	3.23e-06	8.57e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KDR—prostate cancer	3.23e-06	8.56e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.21e-06	8.51e-05	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	3.2e-06	8.48e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—AKR1C3—prostate cancer	3.17e-06	8.4e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PRKACB—prostate cancer	3.15e-06	8.36e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ESR1—prostate cancer	3.15e-06	8.34e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP17A1—prostate cancer	3.12e-06	8.27e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CASP9—prostate cancer	3.11e-06	8.26e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—TYMS—prostate cancer	3.08e-06	8.18e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.08e-06	8.16e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—BAD—prostate cancer	3.07e-06	8.14e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTM1—prostate cancer	3.05e-06	8.08e-05	CbGpPWpGaD
Drospirenone—AR—Gene Expression—SERPINE1—prostate cancer	3.03e-06	8.04e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PRKCQ—prostate cancer	3.02e-06	8e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—LPL—prostate cancer	2.99e-06	7.94e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—CTNNB1—prostate cancer	2.98e-06	7.91e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PIK3CG—prostate cancer	2.97e-06	7.89e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—APC—prostate cancer	2.97e-06	7.89e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NCOA2—prostate cancer	2.97e-06	7.88e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IRS1—prostate cancer	2.94e-06	7.8e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—EGF—prostate cancer	2.94e-06	7.8e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP1A1—prostate cancer	2.89e-06	7.66e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FGF10—prostate cancer	2.87e-06	7.6e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ERCC2—prostate cancer	2.87e-06	7.6e-05	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—AKT1—prostate cancer	2.87e-06	7.6e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—GSK3B—prostate cancer	2.85e-06	7.57e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—SLC5A5—prostate cancer	2.84e-06	7.52e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—INS—prostate cancer	2.82e-06	7.47e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP2E1—prostate cancer	2.77e-06	7.34e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CREBBP—prostate cancer	2.76e-06	7.31e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NQO1—prostate cancer	2.74e-06	7.26e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TGFBR2—prostate cancer	2.73e-06	7.23e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IGF1—prostate cancer	2.72e-06	7.22e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—TH—prostate cancer	2.7e-06	7.16e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—MTHFR—prostate cancer	2.69e-06	7.15e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ITPR1—prostate cancer	2.68e-06	7.12e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.68e-06	7.11e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP3A4—prostate cancer	2.67e-06	7.08e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PPARA—prostate cancer	2.64e-06	7.01e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MAP2K1—prostate cancer	2.63e-06	6.98e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP1B1—prostate cancer	2.63e-06	6.96e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PIK3CD—prostate cancer	2.62e-06	6.93e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—SERPINE1—prostate cancer	2.59e-06	6.86e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GGT1—prostate cancer	2.54e-06	6.74e-05	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—MYC—prostate cancer	2.52e-06	6.68e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NCOA1—prostate cancer	2.5e-06	6.64e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FGF2—prostate cancer	2.5e-06	6.64e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CAV1—prostate cancer	2.49e-06	6.59e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NOS3—prostate cancer	2.47e-06	6.55e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP19A1—prostate cancer	2.47e-06	6.54e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—LPL—prostate cancer	2.46e-06	6.52e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PDGFRB—prostate cancer	2.44e-06	6.46e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—JAK2—prostate cancer	2.4e-06	6.36e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—RXRA—prostate cancer	2.38e-06	6.32e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.37e-06	6.3e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ERCC2—prostate cancer	2.36e-06	6.25e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MDM2—prostate cancer	2.34e-06	6.21e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.32e-06	6.14e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ERBB2—prostate cancer	2.31e-06	6.12e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ERBB3—prostate cancer	2.3e-06	6.11e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FGFR2—prostate cancer	2.3e-06	6.1e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—COMT—prostate cancer	2.29e-06	6.08e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTP1—prostate cancer	2.28e-06	6.06e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PIK3CB—prostate cancer	2.28e-06	6.04e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PIK3CG—prostate cancer	2.26e-06	6e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ITPR1—prostate cancer	2.25e-06	5.96e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MTHFR—prostate cancer	2.21e-06	5.87e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.21e-06	5.86e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TERT—prostate cancer	2.21e-06	5.86e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CXCL8—prostate cancer	2.19e-06	5.81e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—INS—prostate cancer	2.14e-06	5.68e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CDKN1B—prostate cancer	2.14e-06	5.67e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—TYMS—prostate cancer	2.12e-06	5.63e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HIF1A—prostate cancer	2.11e-06	5.6e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CREBBP—prostate cancer	2.1e-06	5.57e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTM1—prostate cancer	2.1e-06	5.56e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CASP3—prostate cancer	2.1e-06	5.56e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IL2—prostate cancer	2.09e-06	5.55e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—LPL—prostate cancer	2.06e-06	5.46e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CAV1—prostate cancer	2.04e-06	5.42e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CCND1—prostate cancer	2.04e-06	5.41e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CTNNB1—prostate cancer	2.02e-06	5.36e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PIK3CD—prostate cancer	1.99e-06	5.28e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP1A1—prostate cancer	1.99e-06	5.28e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MMP9—prostate cancer	1.98e-06	5.25e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CDKN1A—prostate cancer	1.97e-06	5.23e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ERCC2—prostate cancer	1.97e-06	5.23e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PTEN—prostate cancer	1.97e-06	5.22e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—BAD—prostate cancer	1.92e-06	5.09e-05	CbGpPWpGaD
Drospirenone—AR—Gene Expression—MYC—prostate cancer	1.92e-06	5.09e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NOS3—prostate cancer	1.88e-06	4.98e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—EP300—prostate cancer	1.88e-06	4.98e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—APC—prostate cancer	1.86e-06	4.93e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—MTHFR—prostate cancer	1.85e-06	4.92e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—IRS1—prostate cancer	1.84e-06	4.88e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—EGF—prostate cancer	1.84e-06	4.88e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—SRC—prostate cancer	1.83e-06	4.84e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PPARA—prostate cancer	1.82e-06	4.82e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—GSK3B—prostate cancer	1.79e-06	4.73e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—VEGFA—prostate cancer	1.78e-06	4.72e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—STAT3—prostate cancer	1.76e-06	4.67e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—INS—prostate cancer	1.76e-06	4.67e-05	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—AKT1—prostate cancer	1.75e-06	4.63e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PIK3CB—prostate cancer	1.73e-06	4.6e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CREBBP—prostate cancer	1.73e-06	4.57e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PTGS2—prostate cancer	1.72e-06	4.56e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CAV1—prostate cancer	1.71e-06	4.54e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MAP2K1—prostate cancer	1.65e-06	4.37e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MYC—prostate cancer	1.64e-06	4.34e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PIK3CD—prostate cancer	1.64e-06	4.34e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.63e-06	4.33e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TGFB1—prostate cancer	1.63e-06	4.33e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—SERPINE1—prostate cancer	1.62e-06	4.29e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—EGFR—prostate cancer	1.6e-06	4.25e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FGF2—prostate cancer	1.57e-06	4.15e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PIK3CG—prostate cancer	1.56e-06	4.13e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NOS3—prostate cancer	1.54e-06	4.1e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KRAS—prostate cancer	1.51e-06	4.01e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—JAK2—prostate cancer	1.5e-06	3.98e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PTEN—prostate cancer	1.5e-06	3.97e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—INS—prostate cancer	1.48e-06	3.91e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MDM2—prostate cancer	1.47e-06	3.89e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CREBBP—prostate cancer	1.44e-06	3.83e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ERBB2—prostate cancer	1.44e-06	3.83e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—EP300—prostate cancer	1.43e-06	3.79e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PIK3CB—prostate cancer	1.43e-06	3.78e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PIK3CA—prostate cancer	1.39e-06	3.68e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PIK3CD—prostate cancer	1.37e-06	3.63e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TP53—prostate cancer	1.34e-06	3.56e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CDKN1B—prostate cancer	1.34e-06	3.55e-05	CbGpPWpGaD
Drospirenone—AR—Gene Expression—AKT1—prostate cancer	1.33e-06	3.53e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NOS3—prostate cancer	1.29e-06	3.43e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CTNNB1—prostate cancer	1.26e-06	3.35e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CDKN1A—prostate cancer	1.23e-06	3.27e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PTEN—prostate cancer	1.23e-06	3.27e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IL6—prostate cancer	1.23e-06	3.26e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PIK3CB—prostate cancer	1.19e-06	3.17e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—EP300—prostate cancer	1.18e-06	3.12e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—SRC—prostate cancer	1.14e-06	3.03e-05	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—AKT1—prostate cancer	1.14e-06	3.01e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—STAT3—prostate cancer	1.1e-06	2.92e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PIK3CA—prostate cancer	1.06e-06	2.8e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PTEN—prostate cancer	1.03e-06	2.74e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MYC—prostate cancer	1.02e-06	2.71e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TGFB1—prostate cancer	1.02e-06	2.71e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—EGFR—prostate cancer	1e-06	2.66e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—EP300—prostate cancer	9.84e-07	2.61e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—KRAS—prostate cancer	9.46e-07	2.51e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PIK3CA—prostate cancer	8.69e-07	2.3e-05	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—AKT1—prostate cancer	8.64e-07	2.29e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—IL6—prostate cancer	7.7e-07	2.04e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PIK3CA—prostate cancer	7.28e-07	1.93e-05	CbGpPWpGaD
Drospirenone—PTGS2—Disease—AKT1—prostate cancer	7.1e-07	1.88e-05	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—AKT1—prostate cancer	5.95e-07	1.58e-05	CbGpPWpGaD
